According to a study, a Brazilian city cut hospitalizations and mortality in half by offering Ivermectin to everyone pre-vaccine.
During the start of the pandemic, Ivermectin was introduced as a prophylaxis against the disease in the southern Brazilian city of Itajai.
In the span of July and December 2020, approximately 220,000 people received 0.2 mg/kg/day (approximately 18 mg per person weighing 200 pounds) as a two-day treatment option once per every two weeks.
133,051 people received them and 87,466 did not receive them.
After reviewing the data, a team of researchers from various Brazilian institutes, the University of Toronto and EAFIT in Colombia concluded in an initial pre-print version of the study (read below) released in December that hospitalization and mortality rates had been reduced in the Ivermectin group over the period of seven months.
This is even more impressive when you learn the IVM users were older on average, with 30% >50 yo versus 20% for non-IVM users. The mortality reduction is even higher looking at different age groups. 85% for 31-49 yo and 59% for >50 yo. pic.twitter.com/K6D5naybCS— Simon Vallée (@sival84) December 11, 2021
The authors adjusted for the relevant intervention variables, including age, gender, medical history, previous illness, and other conditions.
This analysis contrasts with the October Business Insider report which claims the experiment failed based on anecdotal evidence from Brazilian ICU doctor.
The authors note, “Being a retrospective observational analysis, it is uncertain whether results would be reproducible in a randomized, placebo-controlled, double-blind clinical trial, but likely, since groups of ivermectin users and non-users had similar demographic characteristics, and rates were adjusted for the relevant confounding variables.”
Without any doubt, the ‘fact checkers’ are working very hard to get the pre-print debunked. But they might be better off if they took a peek into ivmmeta.com – a real-time meta-analysis of 70 studies showing Ivermectin’s effectiveness of 83% as a prophylaxis.
It was visibly effective in 70% of the time as an early treatment and 39% effective as a later treatment, according peer-reviewed studies.
Recently, an elderly patient was given Remedesivir to treat Covid-19 in an Illinois hospital, but it could not treat the patient. This hospital was insisting on administering this drug. But, the patient was recovered with Ivermectin when court allowed him to use it despite the hospital’s objections.
Meanwhile, the Indian Bar Association has taken legal action against the World Health Organization’s (WHO) Chief Scientist Dr. Soumya Swaminathan for her role in spreading disinformation and suppressing data on the use of Ivermectin to treat COVID-19.
Read the study below: